denosumab

08/01/2013 - "Denosumab is superior to ZA in preventing complications for patients with bone metastases. "
07/01/2012 - "Denosumab has been shown to be effective in prolonging time to first SRE in clinical settings, however, critical questions remain on its ability to affect bone metastases in mCRPC. "
01/01/2013 - "Based on our first experience, combined treatment of bone metastases with Sm-153 oxabifore and Denosumab is effective and safe. "
01/01/2016 - "Here, we describe safety results of extended denosumab therapy in patients with bone metastases from the open-label extension phase of two phase 3 trials. "
09/01/2014 - "This paper summarizes the treatment possibilities of bone metastasis and presents the results of phase III trials of denosumab and Ra-223-chloride. "

12/01/2011 - "Denosumab offers a highly effective and safe parenteral therapy for osteoporosis and is being studied long term with the extension of the FREEDOM trial, and in other osteoporotic states - in men and glucocorticoid-induced osteoporosis."
01/01/2014 - "Denosumab appears to be a promising, highly effective, and safe parenteral therapy with good adherence for osteoporosis. "
03/01/2015 - "Denosumab is an efficacious and safe osteoporosis treatment option, with current data from up to 8 years of continued use showing continued improvement in bone density with sustained fracture risk reduction. "
07/01/2014 - "Denosumab 60 mg sc injection every 6 months for 36 months was well tolerated and effective in reducing the incidence of vertebral, nonvertebral, and hip fracture in predominantly Caucasian postmenopausal women with osteoporosis. "
02/23/2006 - "These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. "

07/01/2014 - "The authors describe the case of 22-year-old female patient, harboring a GCT involving the C2 vertebral body and odontoid process, who was treated in monotherapy with denosumab, resulting in complete long-term clinical and radiographic tumor remission. "
08/15/2012 - "Denosumab treatment of patients with GCTB significantly reduced or eliminated RANK-positive tumor giant cells. "
07/01/2015 - "Discontinuation of denosumab may be effective in the management of denosumab-related ONJ, depending on the primary tumor control."
09/01/2011 - "The efficacy of RANKL inhibition with denosumab in other disease states in the cancer setting continues to be evaluated."
01/01/2013 - "The outcomes of several international Phase III clinical trials currently underway will help clarify the role of denosumab in patients undergoing cancer therapy. "

12/01/2010 - "In a large (n= 1468), well designed, multinational, phase III trial in adult patients with prostate cancer who were receiving androgen-deprivation therapy, bone mineral density (BMD) at the lumbar spine was significantly improved from baseline after 24 (primary endpoint) and 36 months of treatment with subcutaneous denosumab (60 mg once every 6 months), relative to that with placebo. "
01/01/2013 - "In breast and prostate cancer, denosumab was effective in reducing skeletal morbidity rate compared with placebo. "
02/01/2012 - "Based on these evidences, it has been proved that denosumab is effective in many different stages across the disease continuum of advanced prostate cancer. "
01/01/2016 - "Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer."
06/01/2013 - "However, in a large phase III trial, denosumab has been shown to reduce vertebral fractures in men receiving ADT for prostate cancer. "

10/01/2015 - "Denosumab is effective in reducing the risk of new vertebral fractures, but its effectiveness on pain relief and improvement of the quality of life in patients with spine fractures are not well known. "
01/01/2013 - "Denosumab is effective in preventing SRE, but the effect on pain and QoL is unclear."
08/01/2012 - "Denosumab was effective for prolonging the time to skeletal-related events and inhibiting the onset of pain via the suppression of osteoclast activation. "
02/15/2013 - "Denosumab demonstrated improved pain prevention and comparable pain palliation compared with ZA. "
09/01/2014 - "This analysis of data from an ongoing, open-label study describes denosumab's effects on pain and analgesic use in patients with GCTB. "